Syros Pharmaceuticals, Inc. - common stock (SYRS): Price and Financial Metrics


Syros Pharmaceuticals, Inc. - common stock (SYRS)

Today's Latest Price: $10.44 USD

0.89 (-7.86%)

Updated Jan 27 4:00pm

Add SYRS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

SYRS Stock Summary

  • With a one year PEG ratio of 4,997.78, Syros Pharmaceuticals Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 99.18% of US stocks.
  • SYRS's price/sales ratio is 52.41; that's higher than the P/S ratio of 94.41% of US stocks.
  • As for revenue growth, note that SYRS's revenue has grown 318.38% over the past 12 months; that beats the revenue growth of 97.81% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Syros Pharmaceuticals Inc are CNCE, AGIO, CMRX, DRNA, and ALPN.
  • Visit SYRS's SEC page to see the company's official filings. To visit the company's web site, go to www.syros.com.

SYRS Stock Price Chart Interactive Chart >

Price chart for SYRS

SYRS Price/Volume Stats

Current price $10.44 52-week high $15.65
Prev. close $11.33 52-week low $4.26
Day low $10.23 Volume 797,733
Day high $11.35 Avg. volume 913,718
50-day MA $10.68 Dividend yield N/A
200-day MA $10.14 Market Cap 586.70M

Syros Pharmaceuticals, Inc. - common stock (SYRS) Company Bio


Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases. The company was founded in 2011 and is based in Cambridge, Massachusetts.


SYRS Latest News Stream


Event/Time News Detail
Loading, please wait...

SYRS Latest Social Stream


Loading social stream, please wait...

View Full SYRS Social Stream

Latest SYRS News From Around the Web

Below are the latest news stories about Syros Pharmaceuticals Inc that investors may wish to consider to help them evaluate SYRS as an investment opportunity.

Syros prices $75.6M stock offering

Syros Pharmaceuticals (SYRS) has priced its public offering of 5.4M common shares at $14.00/share, which would result in gross proceeds of ~$75.6M.Underwriters' over-allotment is an additional 810K shares.The proceeds are expected to be used for the development of ongoing clinical and preclinical programs, for working capital and other general corporate...

Seeking Alpha | January 20, 2021

Syros Announces Pricing of $75.6 Million Public Offering of Common Stock

Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, announced today that it has priced an underwritten public offering of 5,400,000 shares of common stock at a public offering price of $14.00 per share, which would result in gross proceeds of approximately $75.6 million, before underwriting discounts and commissions. The proceeds of the offering are expected to be used to fund the development of Syros’ ongoing clinical and preclinical programs, and for working capital and other general corporate purposes. All shares are being offered by Syros. Closing of the offering is expected to occur on or about January 22, 2021, subject to customary closing conditions. Syros has also granted the underwriters a 30-day option to purchas...

Yahoo | January 20, 2021

Syros Announces Strategic Priorities and Expected Milestones

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today outlined its strategic priorities and expected upcoming milestones.

Yahoo | January 11, 2021

Syros to Present at 39th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the virtual 39th Annual J.P. Morgan Healthcare Conference. Details are as follows: 39th Annual J.P. Morgan Healthcare Conference: Date: Thursday, January 7 Time: 2:50 p.m. ET A live webcast of the presentation will be available on the Inve

Business Wire | January 7, 2021

CORRECTING and REPLACING Syros to Present at 39th Annual J.P. Morgan Healthcare Conference

Conference date in details should read: Thursday, January 14 (instead of Thursday, January 7)

Yahoo | January 7, 2021

Read More 'SYRS' Stories Here

SYRS Price Returns

1-mo -14.14%
3-mo 51.74%
6-mo 10.01%
1-year 43.80%
3-year -2.61%
5-year N/A
YTD -3.78%
2020 57.02%
2019 24.06%
2018 -42.75%
2017 -19.98%
2016 N/A

Continue Researching SYRS

Want to see what other sources are saying about Syros Pharmaceuticals Inc's financials and stock price? Try the links below:

Syros Pharmaceuticals Inc (SYRS) Stock Price | Nasdaq
Syros Pharmaceuticals Inc (SYRS) Stock Quote, History and News - Yahoo Finance
Syros Pharmaceuticals Inc (SYRS) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8155 seconds.